Sheetal Hardikar1, Lisa G Johnson2, Mari Malkki3, Effie W Petersdorf3, Denise A Galloway4, Stephen M Schwartz1, Margaret M Madeleine5. 1. Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Epidemiology, University of Washington, Seattle, WA, USA. 2. Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 3. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 4. Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 5. Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Epidemiology, University of Washington, Seattle, WA, USA. Electronic address: mmadelei@fredhutch.org.
Abstract
OBJECTIVE: Persistent infection with oncogenic human papillomavirus (HPV) is known to be the necessary cause of cervical cancer and a majority of vulvar cancers. Persistent HPV infections must evade host immune responses, including cytokines released by activated T-helper (Th) cells. In this study, we investigated the risk of cervical and vulvar cancers associated with common genetic variations in 560 tagging single-nucleotide polymorphisms (SNPs) in candidate cytokine genes. METHODS: The study included 399 invasive squamous cell carcinomas (SCCs) and 502 in situ or invasive adenocarcinomas (AC) of the cervix; 357 in situ or invasive vulvar SCC; and 1109 controls from the Seattle-area case-control studies of HPV-related cancers. Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) using a log additive model, with adjustment for multiple testing. RESULTS: Statistically significant risks were observed for HPV16-containing SCC of the cervix with the variant allele rs879576 in IL17RA and rs2229094 in TNF [OR, 95% CI and multiple-testing corrected p: 1.91 (1.30-2.79), p=0.018 and 0.61 (0.45-0.83), p=0.02, respectively]. We also observed significantly increased risk of HPV-positive vulvar cancers associated with variant alleles in CSF2 (rs25882 and rs27438, 26-28% increased risk) and IL-12B (rs2569254 and rs3181225, 40-41% increased risk) genes. CONCLUSIONS: We found that variation in several Th-cytokine genes is significantly associated with cervical and vulvar cancer risk. The strong association between these HPV-related cancers and common variation in cytokine genes in the Th1 and Th17 pathways may be important for development of new therapies.
OBJECTIVE: Persistent infection with oncogenic human papillomavirus (HPV) is known to be the necessary cause of cervical cancer and a majority of vulvar cancers. Persistent HPV infections must evade host immune responses, including cytokines released by activated T-helper (Th) cells. In this study, we investigated the risk of cervical and vulvar cancers associated with common genetic variations in 560 tagging single-nucleotide polymorphisms (SNPs) in candidate cytokine genes. METHODS: The study included 399 invasive squamous cell carcinomas (SCCs) and 502 in situ or invasive adenocarcinomas (AC) of the cervix; 357 in situ or invasive vulvar SCC; and 1109 controls from the Seattle-area case-control studies of HPV-related cancers. Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) using a log additive model, with adjustment for multiple testing. RESULTS: Statistically significant risks were observed for HPV16-containing SCC of the cervix with the variant allele rs879576 in IL17RA and rs2229094 in TNF [OR, 95% CI and multiple-testing corrected p: 1.91 (1.30-2.79), p=0.018 and 0.61 (0.45-0.83), p=0.02, respectively]. We also observed significantly increased risk of HPV-positive vulvar cancers associated with variant alleles in CSF2 (rs25882 and rs27438, 26-28% increased risk) and IL-12B (rs2569254 and rs3181225, 40-41% increased risk) genes. CONCLUSIONS: We found that variation in several Th-cytokine genes is significantly associated with cervical and vulvar cancer risk. The strong association between these HPV-related cancers and common variation in cytokine genes in the Th1 and Th17 pathways may be important for development of new therapies.
Authors: Christina Gosmann; Stephen R Mattarollo; Jennifer A Bridge; Ian H Frazer; Antje Blumenthal Journal: J Immunol Date: 2014-07-25 Impact factor: 5.422
Authors: J J Carter; M M Madeleine; K Shera; S M Schwartz; K L Cushing-Haugen; G C Wipf; P Porter; J R Daling; J K McDougall; D A Galloway Journal: Cancer Res Date: 2001-03-01 Impact factor: 12.701
Authors: N Saeki; D H Kim; T Usui; K Aoyagi; T Tatsuta; K Aoki; K Yanagihara; M Tamura; H Mizushima; H Sakamoto; K Ogawa; M Ohki; T Shiroishi; T Yoshida; H Sasaki Journal: Oncogene Date: 2007-04-30 Impact factor: 9.867
Authors: Margaret M Madeleine; Lisa G Johnson; Anajane G Smith; John A Hansen; Brenda B Nisperos; Sue Li; Lue-Ping Zhao; Janet R Daling; Stephen M Schwartz; Denise A Galloway Journal: Cancer Res Date: 2008-05-01 Impact factor: 12.701
Authors: Shehnaz K Hussain; Margaret M Madeleine; Lisa G Johnson; Qin Du; Mari Malkki; Hui-Wen Wilkerson; Federico M Farin; Joseph J Carter; Denise A Galloway; Janet R Daling; Effie W Petersdorf; Stephen M Schwartz Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-07 Impact factor: 4.254
Authors: Lily E Kisia; Qiuying Cheng; Evans Raballah; Elly O Munde; Benjamin H McMahon; Nick W Hengartner; John M Ong'echa; Kiprotich Chelimo; Christophe G Lambert; Collins Ouma; Prakasha Kempaiah; Douglas J Perkins; Kristan A Schneider; Samuel B Anyona Journal: Trop Med Health Date: 2022-06-25
Authors: Paul J Leo; Margaret M Madeleine; Sophia Wang; Stephen M Schwartz; Felicity Newell; Ulrika Pettersson-Kymmer; Kari Hemminki; Goran Hallmans; Sven Tiews; Winfried Steinberg; Janet S Rader; Felipe Castro; Mahboobeh Safaeian; Eduardo L Franco; François Coutlée; Claes Ohlsson; Adrian Cortes; Mhairi Marshall; Pamela Mukhopadhyay; Katie Cremin; Lisa G Johnson; Cornelia L Trimble; Suzanne Garland; Sepehr N Tabrizi; Nicolas Wentzensen; Freddy Sitas; Julian Little; Maggie Cruickshank; Ian H Frazer; Allan Hildesheim; Matthew A Brown Journal: PLoS Genet Date: 2017-08-14 Impact factor: 5.917
Authors: Akash M Mehta; Merel Mooij; Ivan Branković; Sander Ouburg; Servaas A Morré; Ekaterina S Jordanova Journal: J Immunol Res Date: 2017-02-09 Impact factor: 4.818
Authors: Sarah J Bowden; Barbara Bodinier; Ilkka Kalliala; Verena Zuber; Dragana Vuckovic; Triada Doulgeraki; Matthew D Whitaker; Matthias Wielscher; Rufus Cartwright; Konstantinos K Tsilidis; Phillip Bennett; Marjo-Riitta Jarvelin; James M Flanagan; Marc Chadeau-Hyam; Maria Kyrgiou Journal: Lancet Oncol Date: 2021-04 Impact factor: 54.433